SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

The World Cup warning: Riots don’t start in the streets. They start online

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

1

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

2

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

3

Echo: “Employees have become very good at identifying performative culture”

4

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

5

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

Pharmaceuricals

3 stories about Pharmaceuricals

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman

The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman

Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines

United Therapeutics to Acquire Pharma Company SteadyMed in a $216 Deal

30.04.18|Amarelle Wenkert

In 2017, Israeli-founded SteadyMed won a patent war against United Therapeutics